The in vitro activity of Sch 34343, a new penem antibiotic, was compared with those of imipenem, vancomycin, and eight other antibiotics against gram-positive bacteria. Ninety percent of methicillin-susceptible Staphylococcus aureus and penicillin-susceptible streptococcal isolates were inhibited by Sch 34343 at concentrations of <0.125 ,ug/ml. Listeria monocytogenes isolates were susceptible to the penem at concentrations of <0.25 ,ug/ml. Penicillin-resistant pneumococci and viridans streptococci were relatively resistant to Sch 34343 (MIC for 90% of the isolates, 4 ,ug/ml), as were methicillin-resistant strains of S. aureus (MIC for 90% of the isolates, .256 ,ug/ml). All 48 strains of Streptococcus faecalis were inhibited by concentrations of c8 ,ug of the drug per ml. Combinations of Sch 34343 with gentamicin demonstrated bactericidal synergism against 5 of 10 enterococcal strains tested in broth media and against 6 of 10 strains tested in 50% pooled human serum. The serum protein binding of Sch 34343 was ca. 65%. The antibacterial activity of Sch 34343 remained stable after 24 h of incubation at 37°C in water or Dextrose-Phosphate broth. However, 63% of bioassayable activity was lost after 24 h of incubation at 37°C in 50% human serum buffered with HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (pH 7.4).
hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (pH 7.4).
Sch 34343 is a recently developed penem antibiotic which is structurally related to the previously described penem Sch 29482 (4) . Preliminary evidence suggests that the new drug is active against a broad range of gram-positive and gram-negative bacteria, with the notable exception of Pseudomonas aeruginosa.
The present study examined the in vitro activity of Sch 34343 against a variety of gram-positive bacteria, including strains of methicillin-resistant staphylococci and penicillinresistant pneumococci and viridans streptococci. Activity of the new penem was compared with those of other parenteral antibiotics which are active against gram-positive organisms, including imipenem, vancomycin, and several third-generation cephalosporins. Since currently approved ,-lactam antibiotics which resist hydrolysis by staphylococcal ,-lactamases generally demonstrate poor activity against enterococci (5), the bactericidal activity of Sch 34343 alone and in combination with gentamicin was studied in a broth medium and in the presence of 50% human serum.
MATERIALS AND METHODS
Organisms. Penicillin-resistant pneumococci and viridans streptococci used in this study had been collected in South Africa as previously described (3) . Other bacteria were clinical isolates from the Massachusetts General Hospital and the New England Deaconess Hospital, Boston, Mass. Antibiotics. Standard laboratory antibiotic reference powders were provided by the following: Sch (8) with Mueller-Hinton agar (BBL Microbiology Systems, Cockeysville, Md.) which was supplemented with 5% defibrinated sheep blood when testing nonenterococcal streptococci. Inocula were prepared by suspending several bacterial colonies from blood agar plates in Mueller-Hinton broth (BBL) to a density of ca. 107 CFU/ml. Final inocula of ca. 104 CFU were applied to plates with a 32-prong inoculator. Plates were examined for growth after 18 to 20 h of incubation in room air at 37°C.
Bactericidal synergism. Tests for the bactericidal effect of Sch 34343, alone and in combination with gentamicin, against enterococci were performed by the time-kill curve methods previously described (5) . Studies were carried out in Dextrose-Phosphate broth (GIBCO Diagnostics, Madison, Wis.) and simultaneously in glucose phosphate broth supplemented with 50% pooled human serum. When serum was used, 50 mM HEPES buffer (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (pH 7.4) was added to ensure maintenance of appropriate pH of the medium (5). Gentamicin was added at a concentration of 5 ,ug/ml, except for two strains for which a concentration of 2.5 p.g/ml was used because of slight inhibition of growth at the higher concentration. Sch 34343 was added at a concentration of 10 or 20 ,ug/ml, concentrations chosen to equal at least twice the MIC required to inhibit the test organism. Synergism was defined as a 100-fold or greater enhancement of killing by the antibiotic combination compared with Sch 34343 alone after 24 h of incubation.
Serum protein binding. The binding of Sch 34343 to pooled human serum was determined by an ultrafiltration technique (1) . Serum specimens were spiked with the penem at concentrations of 20 and 100 ,ug/ml and spun through Amicon filter cones (Amicon Corp., Danvers, Mass.) impermeable to molecules larger than 25,000 molecular weight. Concentrations of Sch 34343 in the resulting ultrafiltrate and in the penem varied over a wide range; activity of the drug was comparable with that of imipenem against these isolates. All strains of Streptococcus faecalis were inhibited by Sch 34343 at concentrations of s8 ,ug/ml. As noted with other P-lactams, the penem was considerably less active against Streptococcusfaecium. Streptococci of groups A, B, C, and G and penicillin-susceptible viridans streptococci were highly susceptible to Sch 34343 (MIC for 90% of the isolates, c0.125 ,Lg/ml). Penicillin-resistant pneumococci and viridans streptococci were relatively resistant to Sch 34343 (MIC for 90% of the isolates, 4 ,ug/ml), but the penem was two-to fourfold more active than penicillin against these strains. Only imipenem was more active than Sch 34343 against Listeria monocytogenes. Failure to demonstrate synergism against the remaining strains was due largely to the excellent bactericidal activity of the penem (mean log10 reduction in CFU per milliliter relative to inoculum, 4.0) rather than to poor activity of the combination (mean log10 reduction in CFU per milliliter relative to inoculum, 5.5) .
In 50% serum, combinations of Sch 34343 with gentamicin were synergistic against 6 of 10 strains of Streptococcus faecalis, including the 5 strains which were synergistically killed by the combination in broth alone. The combination led to a mean reduction of 3 log10 CFU/mi relative to that seen with the penem alone. At 4 h of incubation, 2 log10 or greater enhancement of killing by the combination was seen with 5 of the 10 strains tested. Among the strains which were not killed synergistically, Sch 34343 alone led to a mean log10 reduction in CFU per milliliter of 3.4, and the combination resulted in a reduction of 3.6 log10 CFU/ml, relative to the inoculum, after 24 h of incubation.
Antibiotic stability. In the presence of 50% human serum, exposure of bacterial cultures to the penem at concentrations of <2.5 x the MIC frequently led to a reduction in CFU at 4 h, followed by regrowth of bacteria to levels equal to or greater than the initial inoculum (Fig. 1) . To test the possibility that regrowth seen at 24 h of incubation might be due to loss of the biological activity of the drug, samples of distilled water, Dextrose-Phosphate broth, and 50% human serum in Dextrose-Phosphate broth were spiked with Sch 34343 at a concentration of 100 ,ug/ml and incubated at 5 or 37°C. After 24 h, samples incubated at 5°C in any medium showed no loss of bioassayable antibacterial activity. Similarly, there was no loss of activity when the drug was incubated at 37°C in water or Dextrose-Phosphate broth. In contrast, the sample incubated at 37°C in 50% human serum showed loss of activity of ca. 87%, associated with a rise in pH of the medium after 24 h of incubation (Table 2) . When HEPES buffer was added to 50% serum in Dextrose-Phosphate broth, there was virtually no change in the pH of the medium, but a 63% reduction in bioassayable activity occurred nevertheless. The addition of HEPES to 50% human serum in Dextrose-Phosphate broth also adequately buffered any pH change which could be attributable to the growth of Streptococcus faecalis under conditions of our synergy studies. In a sample culture, the pH of this medium did not change after 24 h of incubation (pH 7.41 at start, pH 7.40 after 24 h), which permitted growth to 4.8 x 107 CFU/ml. Serum protein binding. By the ultrafiltration method employed in this study, Sch 34343 was found to be 67 and 64% bound to human serum proteins when tested at concentrations of 20 and 100 ,ug/ml, respectively.
DISCUSSION
The present study demonstrated that Sch 34343 was active against a broad range of common gram-positive pathogens. A comparison of this data with our previous studies with Sch 29482, the prototype of this class of penem antibiotics, reveals that the new drug is at least as active as Sch 29482 against gram-positive organisms (3). Imipenem, however, was somewhat more active than Sch 34343 against most species examined. The new penem antibiotic appeared to offer no significant advantage over currently available antimicrobial agents against methicillin-resistant strains of Staph- (5) . Such combinations are also ineffective in animal models of enterococcal endocarditis (6) . The lack of influence by human serum on the synergistic potential of Sch 34343-gentamicin combinations is consistent with the observation that the penem is only 65% bound to human serum proteins, a level similar to that previously observed with penicillin G (69% bound) under similar test conditions (5) .
An unexpected finding during the course of our synergy studies was the lack of a substained bactericidal effect of the penem at concentrations near the MIC when tests were carried out in 50% human serum. These results were explained by the observation that although Sch 34343 remained stable for periods of up to 24 h at either 5 or 37°C when dissolved in water or Dextrose-Phosphate broth, there was a significant loss of antimicrobial activity when solutions of the drug in 50% human serum were incubated at 37°C for 24 h. Although the loss of activity was greater in unbuffered human serum in Dextrose-Phosphate broth, which becomes alkaline after incubation in room air, an appreciable reduction in activity also occurred in HEPES-buffered serum-supplemented broth, which undergoes virtually no change in pH with incubation. The structurally related penem Sch 29482 has been previously reported to lose bioactivity at a rate of ca. 6%/h when incubated in serum at 37°C (2) . Future studies of the in vitro effect of Sch 34343 in serum-supplemented media must take this loss of activity into account to prevent underestimation of the antimicrobial activity of the drug. The loss of biological activity of Sch 34343 in serum specimens can be minimized by adjusting the pH to 6.0 with phosphate buffer (G. Miller, personal communication).
Based upon its activity against a variety of gram-positive bacteria, including staphylococci and enterococci, Sch 34343 shows promise as a possible alternative to combinations of penicillins or to vancomycin in the empiric therapy of infections suspected to be caused by gram-positive bacteria. A major exception to this would be in situations in which infection due to methicillin-resistant staphylococci or penicillin-resistant streptococci is likely. Studies currently in progress of the gram-negative and anaerobic activity of the drug will allow definition of the potential clinical role of Sch 34343, particularly in relation to that of imipenem.
